Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2024

 

Commission File Number: 001-40413

 

 

 

Quipt Home Medical Corp.

(Translation of registrant’s name into English)

 

 

 

1019 Town Drive

Wilder, Kentucky 41076

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ¨                Form 40-F  x

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit		Description
99.1		Press Release dated May 9, 2024

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Quipt Home Medical Corp.
Date: May 10, 2024	/s/ Gregory Crawford
	Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

QUIPT HOME MEDICAL CORP. ANNOUNCES FILING OF FINAL BASE SHELF PROSPECTUS

 

Cincinnati, Ohio – May 9, 2024 – Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, has filed and obtained a receipt for its final short form base shelf prospectus (the “Final Shelf Prospectus”) with the securities commissions in each of the provinces and territories of Canada, and a corresponding Amendment No. 2 to the Registration Statement on Form F-10 (File No. 333-276253) previously filed by the Company with the United States ‎Securities and Exchange Commission (the “SEC”) on December 22, 2023 (the “Amended Registration Statement”), with the SEC under the U.S./Canada Multijurisdictional Disclosure System‎. The Final Shelf Prospectus and corresponding Amended Registration Statement enable the Company to offer up to C$300,000,000 of common shares, preferred shares, debt securities, warrants to acquire any of the securities that are described in the Final Shelf Prospectus‎, subscription receipts, and units comprised of any one or more of any of the other securities that are described in the Final Shelf Prospectus‎, or any combination thereof (collectively, the “Securities”) at any time during the 25-month period that the Final Shelf Prospectus remains effective.

 

The Final Shelf Prospectus and corresponding Amended Registration Statement will enable the Company to access new capital or issue securities in connection with strategic acquisitions if and when needed. The amount and timing of any future offerings or issuances will be based on the Company’s financial requirements and market conditions at that time.

 

The terms of future offerings or issuances under the Final Shelf Prospectus, the intended use of the net proceeds resulting from such offerings and the terms of the Securities to be offered, if any, will be established at the time of any such offering and will be described in a prospectus supplement filed with the applicable Canadian securities commissions at the time of such an offering.

 

A copy of the Final Shelf Prospectus is available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, or may be obtained by request from the secretary of the Company at 1019 Town Drive Wilder, Kentucky, USA 41076, telephone: [phone].

 

No securities regulatory authority has either approved or disapproved the contents of this press release. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

 

ABOUT QUIPT HOME MEDICAL CORP.

 

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.

 

For further information please visit our website at www.quipthomemedical.com, or contact:

 

Cole Stevens

VP of Corporate Development

Quipt Home Medical Corp.

859-300-6455

[e-mail]

 

Gregory Crawford

Chief Executive Officer

Quipt Home Medical Corp.

859-300-6455

[e-mail].‎

 

 

 

 

Forward-Looking Statements

 

Certain statements contained in this press release constitute “forward-looking information” as such term is ‎defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, ‎‎“potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar ‎expressions as they relate to the Company, including: future financing opportunities; the filing and effectiveness of any potential prospectus ‎supplement; the amount and terms of any Securities to be offered under one or more shelf prospectus ‎supplement(s); and the Company’s focus on its acquisition strategy, are intended to identify forward-looking ‎information. All statements other than statements of historical fact may be forward-looking information. Such ‎statements reflect the Company’s current views and intentions with respect to future events, and current ‎information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: ‎the acquisition targets achieving results at least as good as historical performances; and the Company ‎successfully identifying, negotiating and completing additional acquisitions, including accretive acquisitions. ‎Many factors could cause the actual results, performance or achievements that may be expressed or implied by ‎such forward-looking information to vary from those described herein should one or more of these risks or ‎uncertainties materialize. Examples of such risk factors include, without limitation: credit; market (including ‎equity, commodity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); ‎reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic ‎conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, ‎including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and ‎pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the ‎Company’s information technology, internet, network access or other voice or data communications systems or ‎services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the ‎failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and ‎changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few ‎payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits ‎and licenses in a highly regulated business; the overall difficult litigation environment, including in the U.S.; ‎increased competition; changes in foreign currency rates; increased funding costs and market volatility due to ‎market illiquidity and competition for funding; the availability of funds and resources to pursue operations; ‎critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; ‎the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and risks ‎related to COVID-19 including various recommendations, orders and measures of governmental authorities to try ‎to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, ‎shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a ‎deterioration of general economic conditions including a possible national or global recession; as well as those risk ‎factors discussed or referred to in the Company’s disclosure documents filed with United States Securities and ‎Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain ‎provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected ‎manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or ‎events may differ materially from the results or events predicted. Any such forward-looking information is ‎expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume ‎responsibility for the accuracy or completeness of such forward-looking information. The forward-looking ‎information included in this press release is made as of the date of this press release and the Company undertakes ‎no obligation to publicly update or revise any forward-looking information, other than as required by applicable ‎law.‎

 

 

 

---